ZPI Inhibitors
ZPI inhibitors refer to a class of chemical compounds that specifically target and inhibit the activity of the ZPI (Zinc-dependent proteinase inhibitor) family of enzymes. ZPI, as a protein, plays a key role in regulating the activity of various proteolytic enzymes, often through its interaction with zinc ions. These enzymes are involved in catalytic processes such as proteolysis, where proteins are broken down into smaller polypeptides or amino acids. Inhibition of ZPI enzymes disrupts this regulatory mechanism, which can affect a range of biological processes. The design and synthesis of ZPI inhibitors focus on blocking the active site of the enzyme, typically where zinc ions coordinate with the enzyme's functional groups. ZPI inhibitors often feature ligand groups that can chelate the zinc ion, thereby rendering the enzyme inactive.
The structural diversity of ZPI inhibitors is an important aspect of their chemical nature, as different inhibitors may bind through various mechanisms, including covalent and non-covalent interactions. These inhibitors are studied to understand the molecular architecture of ZPI enzymes and their roles in biochemical pathways. Advanced techniques like X-ray crystallography and molecular docking are commonly used to study the binding affinity and conformational changes induced by ZPI inhibitors. Furthermore, the chemical synthesis of these inhibitors may involve a variety of organic reactions to optimize their binding efficacy and selectivity for ZPI enzymes, including modifications to enhance metal chelation properties. The study of these inhibitors provides insights into the broader mechanisms of metalloprotease regulation and enzymatic control at the molecular level.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This agent may induce demethylation of the ZPI gene promoter, potentially leading to a decrease in ZPI transcription by allowing transcriptional repressors to bind more effectively or by disrupting binding sites for transcriptional activators. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $214.00 $316.00 $418.00 | 7 | |
By inhibiting DNA methyltransferase, 5-Aza-2′-Deoxycytidine could result in the demethylation of CpG islands within the ZPI gene promoter region, potentially resulting in transcriptional silencing of the ZPI gene. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A could directly inhibit histone deacetylase activity, leading to hyperacetylation of histones associated with the ZPI gene. This change may disrupt the recruitment of transcriptional machinery, subsequently decreasing ZPI expression. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Similar to Trichostatin A, Suberoylanilide Hydroxamic Acid could inhibit HDACs leading to increased histone acetylation levels. This alteration may interfere with transcription factor binding or chromatin remodeling complexes that are necessary for ZPI gene transcription, resulting in reduced expression. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Retinoic acid could activate its nuclear receptors and alter the transcription of target genes, including ZPI. By binding to retinoic acid response elements in the promoter region, it could repress transcription of ZPI through recruitment of co-repressor complexes. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin may inhibit the mTOR pathway, which is crucial for mRNA translation. This inhibition could lead to a selective decrease in the translation of mRNAs, including those for ZPI, thereby reducing the overall protein levels. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 may inhibit PI3K, leading to a decrease in Akt phosphorylation and activity. This reduction may lead to a decrease in the transcription of certain genes, potentially including ZPI, by altering the activity of transcription factors or co-regulators involved in ZPI gene expression. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $54.00 | 6 | |
Mithramycin A could bind to GC-rich DNA sequences within the ZPI gene promoter, blocking the binding of Sp1 transcription factor and other regulatory proteins, thereby leading to a reduction in ZPI transcriptional activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
By inhibiting MEK, PD 98059 could downregulate the MAPK/ERK signaling pathway, which might be responsible for activating transcription factors or co-regulators of ZPI gene transcription, leading to a decrease in ZPI expression. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $92.00 $204.00 | 19 | |
Cyclopamine may directly inhibit Smoothened (SMO) in the Hedgehog signaling pathway. If Hedgehog signaling enhances ZPI gene expression, cyclopamine could reduce ZPI levels by preventing activation of the pathway. | ||||||